V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011016 | 330009286 | null | 36.4 | Curative (C) | null | 2015-01-12 | Lenalidomide Cycle 26 onwards (PAS) | Y | null | 330007592 | IVADO |
| 330011017 | 330011058 | 1.77 | 56.5 | Disease modification (D) | 2018-07-20 | 2018-08-05 | UKALL14- Cons Cycle 2 | N | N | 330007632 | UKALL 2011 |
| 330011018 | 330006037 | 1.82 | 50.4 | Curative (C) | 2016-08-31 | 2017-03-16 | Cytarabine Low Dose | N | N | 330007702 | IBRUTINIB |
| 330011019 | 330006038 | 1.71 | 76 | Curative (C) | 2019-02-04 | 2019-02-04 | Cyclophosphamide High Dose | 02 | N | 330007777 | MAP + MIFAMURTIDE |
| 330011020 | 330006039 | 1.65 | 45.3 | Palliative (P) | 2017-07-02 | 2017-07-09 | AML17 TRIAL | Y | null | 330008201 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330011021 | 330006041 | 1.82 | 96.2 | Palliative (P) | 2019-01-25 | 2019-01-28 | FLUOROURACIL + MITOMYCIN + RT | 2 | N | 330008362 | BENDAMUSTINE |
| 330011022 | 330009290 | 1.74 | 11.3 | Disease modification (D) | 2015-04-11 | 2015-04-11 | EDP + MITOTANE | N | N | 330008837 | EMA |
| 330011023 | 330009290 | 1.79 | 80.2 | Curative (C) | 2019-03-03 | 2019-03-03 | Imatinib 400mg | 2 | N | 330008837 | CAPECITABINE |
| 330011024 | 330006045 | null | null | Curative (C) | null | 2018-09-02 | Depocyte Intrathecal | null | null | 330009579 | CARBOPLATIN + CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 330011025 | 330006048 | null | 115 | null | 2013-12-17 | 2014-01-01 | IVADo | N | N | 330009587 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 330011026 | 330006049 | 1.51 | 0 | Palliative (P) | 2017-05-23 | 2017-06-27 | IMATINIB | 01 | N | 330009636 | CARBOPLATIN + CETUXIMAB + FU |
| 330011027 | 330009293 | 1.6 | 65.4 | Palliative (P) | 2017-08-15 | 2018-03-18 | CYCLO + DOXORUBICIN + VINCRISTINE | N | N | 330009760 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330011028 | 330009294 | 0 | null | Curative (C) | 2015-11-07 | 2016-02-03 | IVADo | 1 | N | 330009845 | IFOSFAMIDE |
| 330011029 | 330009294 | null | 92 | Curative (C) | 2015-11-15 | 2015-11-22 | Bortezomib +/- Dexamethasone | N | null | 330009845 | PEMBROLIZUMAB |
| 330011030 | 330013202 | 1.52 | 92.6 | Curative (C) | 2018-02-27 | 2018-03-03 | CNS LGG 2004 03 vinc weekly+ carbo | 2 | N | 330009954 | HYDROXYCARBAMIDE |
| 330011031 | 330006054 | 1.58 | 0 | Palliative (P) | 2018-03-25 | 2018-03-31 | Ifosfamide | 02 | N | 330010132 | CARBOPLATIN + ETOPOSIDE + THIOTEPA |
| 330011032 | 330006057 | 1.82 | 58.9 | Curative (C) | 2015-09-05 | 2015-09-06 | DE-ESCALATE TRIAL | N | N | 330010223 | IFOSFAMIDE |
| 330011033 | 330009299 | 1.72 | 73.9 | Palliative (P) | 2017-02-28 | 2017-03-18 | AML LI-1 Trial | 02 | N | 330010514 | ADE |
| 330011034 | 330006063 | 1.62 | 60 | Palliative (P) | 2015-02-15 | 2015-02-27 | VINCRISTINE | N | N | 330010809 | CAPECITABINE + CISPLATIN |
| 330011035 | 330006066 | null | null | Palliative (P) | 2018-04-02 | 2018-04-02 | MAP + MIFAMURTIDE | N | N | 330010873 | CISPLATIN + GEMCITABINE |
| 330011036 | 330006068 | 1.64 | null | Neo-adjuvant (N) | 2018-09-21 | 2018-09-21 | Cytarabine Intrathecal (any age) | 02 | N | 330011080 | AML17 TRIAL |
| 330011037 | 330009305 | 1.62 | 12.8 | Curative (C) | 2014-06-13 | 2014-07-29 | Dox + HD Mtx (post PAM) | 2 | N | 330011302 | ATG + BUSULFAN + FLUDARABINE |
| 330011038 | 330006072 | 1.71 | 85 | Palliative (P) | 2017-07-23 | 2017-08-26 | Cyclophosphamide + Vincristine | N | N | 330011853 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330011039 | 330009307 | 1.66 | null | Curative (C) | 2017-01-08 | 2017-05-04 | Hydroxycarbamide | 2 | N | 330011918 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330011040 | 330006074 | 1.6 | 8.6 | null | 2014-09-16 | 2014-09-16 | Chlorambucil | Y | N | 330011954 | PONATINIB |
| 330011041 | 330006076 | 1.51 | 67.5 | Palliative (P) | 2018-07-17 | 2018-07-30 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330011961 | DOXORUBICIN + METHOTREXATE |
| 330011042 | 330006077 | 1.82 | 93.8 | Disease modification (D) | 2016-11-03 | 2016-11-05 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 330012226 | BUSULFAN + MELPHALAN |
| 330011043 | 330009311 | 1.38 | 30.4 | Adjuvant (A) | 2015-08-26 | 2015-09-23 | ALL UKALL2011 Consolidation A | 02 | N | 330012831 | AML18 TRIAL |
| 330011044 | 330006079 | 1.84 | 22.6 | Neo-adjuvant (N) | 2017-01-03 | 2017-01-03 | VIDE | 02 | N | 330012831 | BEP |
| 330011045 | 330006079 | 1.68 | 55.9 | Curative (C) | null | 2018-06-07 | CYCLOPHOSPHAMIDE | N | null | 330012831 | TRIPLE INTRATHECAL |
| 330011046 | 330009313 | 1.83 | 66.6 | Palliative (P) | 2018-03-01 | 2018-03-01 | Mitotane 4 - 4.5g | N | N | 330015056 | CLADRIBINE |
| 330011047 | 330006081 | null | 60.8 | Palliative (P) | 2016-06-24 | 2016-06-27 | Cisplatin + Pemetrexed | 2 | N | 330015108 | FLUOROURACIL |
| 330011048 | 330006084 | 1.68 | 71 | Curative (C) | 2019-07-26 | 2019-07-27 | Cyclophosphamide + Vincristine | 02 | N | 330015148 | IVA |
| 330011049 | 330012031 | 1.61 | 65 | Palliative (P) | 2013-08-16 | 2013-08-16 | AML17 TRIAL | 2 | N | 330015213 | CYCLOPHOSPHAMIDE |
| 330011050 | 330006086 | null | 11.2 | Curative (C) | 2016-01-16 | 2016-02-06 | TRASTUZUMAB | N | N | 330015218 | CISPLATIN + VINORELBINE |
| 330011051 | 330006088 | 0 | 60.5 | Adjuvant (A) | 2016-07-06 | 2016-08-08 | Cetuximab+Cisplatin+FU (> Cycle 2) | null | null | 330015310 | POMALIDOMIDE |
| 330011052 | 330009317 | null | 48.8 | Curative (C) | 2015-10-26 | 2016-01-04 | ALL UKALL2011 Maintenance A2 | Y | null | 330015325 | ETOPOSIDE + RITUXIMAB |
| 330011053 | 330009317 | 1.78 | null | Palliative (P) | 2015-02-07 | 2015-02-12 | VINCRISTINE | 02 | N | 330015325 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330011054 | 330009318 | null | 56.4 | Curative (C) | 2017-03-20 | 2017-05-08 | BORTEZOMIB + RITUXIMAB | null | N | 330015442 | MACE |
| 330011055 | 330006093 | null | 72.1 | Palliative (P) | 2013-12-31 | 2014-02-25 | CNS LGG Irinotecan & Bevacizumab | N | null | 330015466 | CARBOPLATIN + VINCRISTINE |
| 330011056 | 330006095 | 1.84 | 106.2 | Curative (C) | 2014-06-23 | 2014-06-23 | CETUXIMAB + CISPLATIN + FU | N | null | 330015473 | CETUXIMAB + CISPLATIN + FU |
| 330011057 | 330009319 | 1.8 | 76.2 | null | 2013-03-06 | 2013-08-09 | IPM | N | N | 330015685 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330011058 | 330006096 | null | null | Curative (C) | 2015-10-02 | 2016-01-21 | CHOP R | N | null | 330015691 | CARBOPLATIN + CETUXIMAB + FU |
| 330011059 | 330006097 | 1.73 | 59 | Palliative (P) | 2015-08-23 | 2015-11-01 | AML 19 TRIAL | N | null | 330015923 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330011060 | 330006097 | 1.81 | 103.3 | null | 2018-05-19 | 2018-05-20 | Dox + HD Mtx (post PAM) | 2 | N | 330015923 | CVD |
| 330011061 | 330009322 | 0 | 53.1 | Curative (C) | 2014-08-22 | 2014-08-22 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | 330016127 | PAZOPANIB |
| 330011062 | 330006100 | 1.76 | 78.2 | Curative (C) | 2018-05-26 | 2018-06-12 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330016561 | CVD |
| 330011063 | 330006100 | 1.87 | null | Palliative (P) | 2014-05-14 | 2014-06-23 | Epirubicin | null | N | 330016561 | IVADO |
| 330011064 | 330011081 | 0 | null | Curative (C) | null | 2017-02-01 | Capecitabine + Streptozocin | N | N | 330017182 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE |
| 330011065 | 330009327 | 1.58 | 59.4 | Palliative (P) | 2018-04-21 | 2018-04-26 | Cisplatin + Fluorouracil + RT 5day | N | N | 330018870 | CARBOPLATIN + CYCLOPHOSPHAMIDE + ETOPOSIDE |